Shares of Theravance Biopharma Inc. (NASDAQ:TBPH) reached a new 52-week high on Thursday . The stock traded as high as $29.15 and last traded at $28.75, with a volume of 124,402 shares. The stock had previously closed at $28.36.

Several research firms have recently weighed in on TBPH. Leerink Swann restated a “buy” rating on shares of Theravance Biopharma in a report on Saturday, June 4th. Bank of America Corp. cut Theravance Biopharma from a “neutral” rating to an “underperform” rating in a report on Wednesday, August 3rd. Guggenheim began coverage on Theravance Biopharma in a report on Monday, June 20th. They issued a “buy” rating and a $30.00 target price on the stock. Zacks Investment Research cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, August 16th. Finally, Evercore ISI began coverage on Theravance Biopharma in a report on Monday. They issued a “buy” rating and a $41.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $32.00.

The stock’s 50-day moving average is $25.70 and its 200 day moving average is $21.68. The firm’s market cap is $1.37 billion.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.01. On average, equities research analysts anticipate that Theravance Biopharma Inc. will post ($4.03) EPS for the current year.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 49,122 shares of the firm’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $27.46, for a total value of $1,348,890.12. Following the sale, the executive vice president now directly owns 241,686 shares in the company, valued at approximately $6,636,697.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brett K. Haumann sold 4,491 shares of the firm’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $27.99, for a total transaction of $125,703.09. Following the completion of the sale, the senior vice president now owns 188,293 shares in the company, valued at $5,270,321.07. The disclosure for this sale can be found here.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.